Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Top T. Rowe Price Fund Manager Shares Her Secrets

Stock picking is the hallmark of top mutual fund T. Rowe Price U.S. Equity Research Fund.

Investors Business Daily

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Barchart

Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales

Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Failure to Warn: The Type of Product Liability Ozempic is Being Sued for

Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. Recently, it has been in the spotlight due to lawsuits being filed against its manufacturer, Novo Nordisk. These lawsuits claim that Ozempic has been linked to a serious gastrointestinal condition called gastroparesis.

inkl

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Fortune

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Roll Call

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Investors Business Daily

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review

The stock market rally revived with the major indexes reclaiming key levels and many top leaders flashing buy signals.

Investors Business Daily

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

StockNews.com

Novo Jumps After Weight-Loss Pill Tops Wegovy; Lilly, Viking Shares Rise

Novo Nordisk stock rose moderately Wednesday after the pharma giant said its new weight-loss drug, amycretin, outperformed Wegovy.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK

Ozempic maker sued over claims the weight-loss medication led to woman’s colon removal

Doctors had to remove parts of her intestines due to what she claims were side effects from taking weight-loss medication

Investors Business Daily

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Inverse

Scientists Confirmed An Important Connection Between Semaglutide and Mental Health

Researchers found that semaglutide, compared with a placebo, didn't significantly increase depressive thoughts.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock edged higher.

Investors Business Daily

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Investors Business Daily

Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.

Eli Lilly and Novo Nordisk kicked off the "vanity trade," but the trend could be extending to other industries as well.

Fortune

Denmark gets Novo Nordisk to lower Ozempic prices

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Investors Business Daily

Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy

Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.

The Guardian - UK

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

Evening Standard

Weight loss drug Ozempic sales grow nearly 50% in the US, says maker Novo Nordisk

A surge in demand for weight loss drug Ozempic has helped Novo Nordisk post a 25% jump in revenues in the first half of the year, the Danish company said today.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.